Published in Alzheimers Res Ther on October 17, 2012
Amyloid Beta and Tau as Alzheimer's Disease Blood Biomarkers: Promise From New Technologies. Neurol Ther (2017) 0.75
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol (2012) 2.61
Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging (2008) 2.51
Human anti-animal antibody interferences in immunological assays. Clin Chem (1999) 2.30
Towards a better understanding of heterophile (and the like) antibody interference with modern immunoassays. Clin Chim Acta (2002) 2.24
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol (2012) 2.22
Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J Immunol Methods (2005) 2.09
Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis (2010) 1.86
Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement (2011) 1.85
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid (2000) 1.75
Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol (2002) 1.68
Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. Ann Neurol (2009) 1.65
Biomarkers in Alzheimer's disease drug development. Nat Med (2010) 1.61
Distinct patterns of antiamyloid-β antibodies in typical and atypical Alzheimer disease. Arch Neurol (2012) 1.44
Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 1.39
A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord (2010) 1.29
Factors affecting the antigen-antibody reaction. Blood Transfus (2007) 1.23
Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging (2004) 1.22
Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs (2010) 1.20
Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol (2001) 1.19
Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A (2007) 1.17
Development of AFFITOPE vaccines for Alzheimer's disease (AD)--from concept to clinical testing. J Nutr Health Aging (2009) 1.07
The war on heterophilic antibody interference. Clin Chem (2005) 1.05
Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis. J Neurochem (2008) 1.03
Inhibition of protein aggregation: supramolecular assemblies of arginine hold the key. PLoS One (2007) 1.02
Brain-reactive autoantibodies prevalent in human sera increase intraneuronal amyloid-β(1-42) deposition. J Alzheimers Dis (2011) 1.01
Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC Neurosci (2007) 1.00
Solanezumab for the treatment of mild-to-moderate Alzheimer's disease. Expert Rev Clin Immunol (2012) 0.97
Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD). Expert Opin Emerg Drugs (2012) 0.97
Interference from heterophilic antibodies in amyloid-β oligomer ELISAs. J Alzheimers Dis (2010) 0.94
Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab. Curr Alzheimer Res (2011) 0.93
Analytical aspects of molecular Alzheimer's disease biomarkers. Biomark Med (2012) 0.93
Measurement of Aβ1-42 in cerebrospinal fluid is influenced by matrix effects. J Neurochem (2011) 0.91
Abeta1-42 Detection in CSF of Alzheimer's disease is influenced by temperature: indication of reversible Abeta1-42 aggregation? Exp Neurol (2009) 0.89
Elevation of {beta}-amyloid 1-42 autoantibodies in the blood of amnestic patients with mild cognitive impairment. Arch Neurol (2010) 0.88
Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease. Clin Neuropharmacol (2012) 0.86
Gantenerumab for the treatment of Alzheimer's disease. Expert Opin Biol Ther (2012) 0.85
Immune complexes of auto-antibodies against A beta 1-42 peptides patrol cerebrospinal fluid of non-Alzheimer's patients. Mol Psychiatry (2007) 0.83
39-week toxicity and toxicokinetic study of ponezumab (PF-04360365) in cynomolgus monkeys with 12-week recovery period. J Alzheimers Dis (2012) 0.81
Development and advanced validation of an optimized method for the quantitation of Aβ42 in human cerebrospinal fluid. AAPS J (2012) 0.81
Dynamic properties of pH-dependent structural organization of the amyloidogenic beta-protein (1-40). Prion (2009) 0.81
Improving immunoassay performance by antibody engineering. Clin Chem (2005) 0.76
The effect of pH on the aggregation of biotinylated antibodies and on the signal-to-noise observed in immunoassays utilizing biotinylated antibodies. J Immunol Methods (1987) 0.76